Category: Uncategorized

The Ketamine Story: Transforming Treatment For Mood Disorders & Pain – YouTube

(1) An Apology From Dr. Smith : TherapeuticKetamine (reddit.com)

Head to head Trial of Prolonged Release Oral Ketamine Formulation | Treating Treatment-Resistant Depression (ketabon.health)

In a first, memory shown to have two distinct past and future paths (newatlas.com)

https://www.sciencedirect.com/science/article/pii/S0165032723006110

Neurons Decoded: The Universal Workflow Powering Brain Insights (scitechdaily.com)

Rewiring the Brain: The Neural Code of Traumatic Memories – Neuroscience News

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis – ScienceDirect

https://www.cureus.com/articles/166047-rapamycin-augmentation-of-chronic-ketamine-as-a-novel-treatment-for-complex-regional-pain-syndrome#!/

Freedom Biosciences Develops Ketamine Combination Therapies – Lucid News

Scientists Identify New Brain Imaging-Based Biomarker of Depression

Stanford Medicine Researchers Discovered A New Depression Subtype Known As The “Cognitive Biotype,” Which Doesn’t Respond Well To Commonly Prescribed Antidepressants (msn.com)

Excellent PodCast. Long but covers a lot of ketamine’s aspects.

Ketamine for the treatment of major depression: a systematic review and meta-analysis – eClinicalMedicine (thelancet.com)

“Findings

The systematic review identified 687 articles, of which 49 RCTs were eligible for analysis, comprising 3299 participants. Standardised mean differences (95% confidence intervals) immediately following the first/single treatment were moderate-high for all conditions (Rac-High: −0.73, −0.91 to −0.56; Esket-High: −0.48, −0.75 to −0.20; Rac-Low: −0.33, −0.54 to −0.12; Esket-Low: −0.55, −0.87 to −0.24). Ongoing effects during repeated dosing were significantly greater than the control for Rac-High (−0.61; −1.02 to −0.20) and Rac-Low (−0.55, −1.09 to −0.00), but not Esket-Low (−0.15, −0.49 to 0.19) or Esket-High (−0.22, −0.54 to 0.10). At follow-up effects remained significant for racemic ketamine (−0.65; −1.23 to −0.07) but not esketamine (−0.33; −0.96 to 0.31). All-cause dropout was similar between experiment and control conditions for both formulations combined (Odds Ratio = 1.18, 0.85–1.64). Overall heterogeneity varied from 5.7% to 87.6%”

As you may know, Vermont has been significantly affected by flooding over the last 48 hours. Flood levels are unprecedented, even compared to devastating flooding during Tropical Storm Irene in 2011.

I wanted to update everyone that our practice structure and operations have not been physically affected by the waters. However, it has affected members of our staff–either directly to their homes or to their family members’ homes and businesses.

For those of you who have reached out to check on us, we all greatly appreciate it. Luckily, we are all safe. If we are slow to answer calls or emails, we have been on a skeleton crew as staff navigate taking care of their affairs and appreciate your patience and understanding. If you worry something has slipped through or not been responded to, you may send an email to me. I have no interruption in power or internet either at home or at work.

Thanks again for everyone who has reached out!

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression | NEJM

Joyous has said they dose less than Dr Smith, so transitioning patients need to wait 30-90 days (in May, until August) before moving to their practice to reset their ketamine tolerance.

Dr Smith’s operations were shut down due to DEA order. Please see our Provider Directory for help finding alternate providers.

DEA extends pandemic-era prescribing measure | The Hill